




Contents lists available at ScienceDirect

Journal of Infection

journal homepage: [www.elsevier.com/locate/jinf](http://www.elsevier.com/locate/jinf)

## Letter to the Editor

### Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China

Dear editor,

The newly emergent Coronavirus disease 2019 (COVID-19) causes severe viral pneumonia in humans and poses a serious threat to public health worldwide, with cases reported from all 6 permanently inhabited continents. Effective clinical management, based on comprehensive laboratory findings, is critical for improving the survival rates of COVID-19 patients. By now, clinical and epidemiological characteristics of COVID-19 in cities outside of Wuhan, such as Beijing<sup>1</sup> and Wenzhou<sup>2</sup> are described. However, it is currently unknown whether there are any markers that can be informative of mild vs. severe disease. The objective of this study is to describe the comprehensive clinical characteristics of confirmed patients with COVID-19 and explore the potential markers correlating with prognosis.

We collected data from 119 hospitalized, symptomatic patients confirmed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) with throat swab specimens in Xiangyang, Hubei Province, between January and February 2020. The severe cases in this study refer to the patients who had enrolled to the intensive care unit (ICU) and received a treatment for more than 3 days, whereas the other confirmed cases were distributed to the mild group. As a control, we collected the laboratory results of 20 healthy subjects (normal cases) examined by the same laboratory department during early December 2019, when COVID-19 was not yet prevalent in Xiangyang. The epidemiological, clinical, laboratory and disease outcome data were obtained from data collection forms and electronic medical records. Information was collected on the date of illness onset, visits to clinical facilities, and hospital admissions. The date of disease onset was defined as the day when the symptom was first noticed. Laboratory tests were conducted at admission, including a complete blood count and serum biochemistry.

As shown in Table 1, we found that 85% (101 cases) of the patients were infected by another COVID-19 patient, 46% (55 cases) of the patients were categorized as collective cases, and 30% (36 cases) of patients were also diagnosed with a pre-existing medical condition. After hospital admission, 16.8% (20 cases) of these patients progressed to severe disease, 4.2% (5 cases) of the patients had complications such as respiratory failure and distress, and 2.5% (3) patients succumbed to COVID-19. Fever was the most common symptom (86%, 102 cases), followed by fatigue (75%, 89 cases) and dry cough (63%, 75 cases). Headache and diarrhea were also reported among 14% (17 cases) and 12% (14 cases) cases, respectively.

Laboratory findings showed that decreased lymphocyte counts (Fig. 1A), as well as elevated levels D-dimer (Fig. 1B), may be early

markers contributing to disease severity. Decreased albumin (Fig. 1C) and elevated CK (Fig. 1D) levels among severe patients indicate liver damage and shown as indicators of prognosis. Increased lactate dehydrogenase (LDH, Fig. 1E) and  $\alpha$ -hydroxybutyrate dehydrogenase (HBDH, Fig. 1F) levels, indicative of heart damage, were detected in COVID-19 patients. Kidney damage in the COVID-19 patients was evidenced by urinary occult blood, increased C1q (Fig. 1G) and  $\beta$ 2-MG (Fig. 1H) in COVID-19 patients.

In the study, we analyzed 119 cases of COVID-19 patients from a local hospital, in which 101 people had no residence or travel history to Wuhan, meaning most of the subjects in this study are non-first-generation cases. While some studies for clinical examinations have been published, many were not comprehensive and the studies took place in Wuhan.<sup>3-6</sup> Especially in the early stages of the outbreak, due to the overwhelmed medical system and lack of adequate medical resources and staff in Wuhan, clinical studies and laboratory examination results may not be reflective of the true nature of COVID-19 in patients. Indeed, this is reflected in the case fatality rates inside (4%) and outside of Wuhan (2.5%, according to our study). While other studies suggest that men are more susceptible to SARS-CoV-2 infection, there were no significant differences in susceptibility to the virus between men and women in our study, even though women had more mild disease cases. The results in this study support the suggestion that there are no significant differences in the levels of ACE2 (the receptor for SARS-CoV-2) expression between genders. As ACE2 is more highly expressed in elderly people, they theoretically would account for a higher percentage of the COVID-19 patients in this study.


Biomarkers that serve as reliable prognostic indicators predicting progression to mild vs. severe disease are urgently needed to enhance the quality of clinical care. In this study, we explored the possibility of identifying markers from a routine comprehensive laboratory examination. Consistent with other studies, we found that decreased lymphocyte counts and increased D-dimer concentrations might be an indication of a negative prognosis and enhanced disease severity. In addition, we provide several newly discovered bio-markers: decreased albumin as well as elevated CK, LDH and HBDH levels serve as indicators of a negative prognosis for COVID-19; urinary occult blood, increased C1q and  $\beta$ 2-MG were observed in COVID-19 patients, indicated kidney damage.

The damage of SARS-CoV-2 to various major tissues and organs of the body during COVID-19 is an important area of investigation. In this study, we found that this virus can cause damage to the liver, heart and kidney, in which abnormal renal indicators may be caused by immunopathological damage. These findings are consistent with recent studies that the virus can damage multiple major organs including liver<sup>7,8</sup> kidney and heart<sup>8</sup>. The exact mechanism of this viral or immune-induced damage should be investigated in future studies.

**Table 1**  
Personal and clinical characteristics of patients with COVID-19 (n = 119).

Characteristics	No. (%)		
	All patients (n = 119)	Mild disease (n = 99)	Severe disease (n = 20)
<b>Median (IQR) age (Y)</b>	49 (38-61)	45 (34-57)	67.5 (60-77)
<b>Age groups (Y):</b>			
≤18	7 (6)	7 (7)	0 (0)
19-40	35 (30)	35 (35)	0 (0)
41-65	55 (46)	46 (46)	9 (45)
≥66	22 (18)	11 (11)	11 (55)
<b>Gender</b>			
Female	63 (53)	55 (56)	8 (40)
Male	56 (47)	44 (44)	12 (60)
<b>Co-morbidities</b>			
Hypertension	36 (30)	18 (18)	17 (85)
Diabetes	23 (19)	10 (10)	13 (65)
Cardiovascular disease	12 (10)	7 (7)	5 (25)
Renal diseases	7 (6)	3 (3)	4 (20)
Liver disease	2 (2)	1 (1)	1 (5)
<b>Travel history to Wuhan</b>			
Yes	2 (2)	2 (2)	0 (0)
No	18 (15)	15 (15)	3 (15)
<b>Cluster cases</b>			
Yes	101 (85)	84 (85)	17 (85)
No	55 (46)	47 (47)	8 (40)
<b>Signs and symptoms</b>			
Fever	102 (86)	86 (86)	16 (80)
Fatigue	89 (75)	75 (75)	14 (70)
Dry cough	75 (63)	63 (53)	13 (65)
Expectoration	22 (18)	16 (16)	6 (30)
Headache	17 (14)	15 (15)	2 (10)
Diarrhea	14 (12)	11 (11)	3 (15)
Pharyngalgia	11 (9)	10 (10)	1 (5)
Palpitation	6 (5)	4 (4)	2 (10)
Nausea and vomiting	4 (3)	3 (3)	1 (5)
Rhinobyon	3 (3)	2 (2)	1 (5)
<b>Routine urinalysis</b>			
Urine protein	21 (18)	21 (18)	0 (0)
Urinary occult blood	14 (12)	14 (12)	0 (0)
<b>Symptom onset to hospital admission, median (IQR), days</b>	5 (3-7)	5(3-7)	5 (4-9)
<b>Symptom onset to laboratory confirmation via qRT-PCR, median (IQR), days</b>	6 (4-9)	6 (4-8)	7 (5-11)
<b>Symptom onset to negative detection via qRT-PCR, median (IQR), days</b>	21 (18-24)	19 (15-21)	25 (23-27)

Abbreviations: IQR, interquartile range; Y, year.

**Fig. 1. Routine blood examination of severe, mild COVID-19 patients, and healthy people upon admission.** (A) Lymphocyte counts and (B) D-dimer concentrations are shown as indicators of coagulation function, (C) Albumin and (D) Creatinine kinase (CK) levels/activities are shown as indicators of liver function, (E) Lactate dehydrogenase (LDH) and (F) -hydroxybutyrate dehydrogenase (HBDH) as indicators of myocardial damage, (G) Complement component 1q (C1q) and (H) 2-microglobulin (2-MG) as indicators for kidney damage. \*P<0.05, \*\*P<0.01 and \*\*\*P<0.001.

## Funding

This work was supported by the Doctoral Fund of Xiangyang Central Hospital (RC202001), the One Belt and One Road major project for infectious diseases (2018ZX10101004-003). Gary WONG is supported by a G4 grant from IP, FMX and CAS.

## References

- Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020 pii: S0163-4453(20)30101-8. doi:10.1016/j.jinf.2020.02.018.
- Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020 pii: S0163-4453(20)30099-2. doi:10.1016/j.jinf.2020.02.016.

3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020. doi:10.1001/jama.2020.1585.
5. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020. doi:10.1016/S0140-6736(20)30360-3.
6. Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020. doi:10.1097/CM9.0000000000000744.
7. Chen N ZM, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;**395**(10223):507–13. doi:10.1016/S0140-6736(20)30211-7.
8. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 novel coronavirus. *Clin Infect Dis* 2020 pii: ciaa112. doi:10.1093/cid/ciaa112.

Liang Shen<sup>1</sup>, Shichao Li<sup>1</sup>, Yufang Zhu<sup>1</sup>, Jianzhong Zhao<sup>1</sup>,  
Xiaoyong Tang<sup>1</sup>

Xiangyang Central Hospital, Affiliated Hospital of Hubei University of  
Arts and Science, Hubei Province, Xiangyang, 441021, China

Huiqin Li

The Second Hospital of Shijiazhuang, 050000, China

Hui Xing

Xiangyang Central Hospital, Affiliated Hospital of Hubei University of  
Arts and Science, Hubei Province, Xiangyang, 441021, China

Mingqing Lu

Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai  
200031, China

Christina Frederick

Department of Microbiology, Biochemistry and Bio-informatics, Laval  
University, Quebec City G1V 4G2, Canada

Canping Huang

Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai  
200031, China

Gary Wong\*\*

Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai  
200031, China

Department of Microbiology-Infectiology and Immunology, Laval  
University, Quebec City G1V 4G2, Canada

Chunhua Wang\*\*

Xiangyang Central Hospital, Affiliated Hospital of Hubei University of  
Arts and Science, Hubei Province, Xiangyang, 441021, China

Jiaming Lan\*

Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai  
200031, China

\*Corresponding author at: CAS Key Laboratory of Molecular  
Virology & Immunology, Institut Pasteur of Shanghai, Chinese  
Academy of Sciences, Shanghai 200031, China.

\*\*Co-corresponding authors.

E-mail addresses: garyckwong@ips.ac.cn (G. Wong),  
wchdye@163.com (C. Wang), jmlan@ips.ac.cn (J. Lan)

<sup>1</sup> These author contributed equally to this article